36E79724R0007 0001.docx

5. PROJECT NUMBER (if applicable)

CODE

7.

ADMINISTERED BY

2. AMENDMENT/MODIFICATION NUMBER

CODE

6. ISSUED BY

8. NAME AND ADDRESS OF CONTRACTOR

4. REQUISITION/PURCHASE REQ. NUMBER

3. EFFECTIVE DATE

9A. AMENDMENT OF SOLICITATION NUMBER

9B. DATED

PAGE OF

PAGES

10A. MODIFICATION OF CONTRACT/ORDER NUMBER

10B. DATED

BPA NO.

1. CONTRACT ID CODE

FACILITY CODE

CODE

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers

E. IMPORTANT:

is extended,

(a) By completing Items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE

OF YOUR

ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY is not extended.

12. ACCOUNTING AND APPROPRIATION DATA

(REV. 11/2016)

is required to sign this document and return ___________ copies to the issuing office.

is not, A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

15C. DATE SIGNED

B. THE ABOVE NUMBERE

D CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES

SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

RESULT IN REJECTION OF YOUR

OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendmen t, and is received prior to the opening hour and date specified.

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER

Contractor

16C. DATE SIGNED

14. DESCRIPTION OF AMENDMENT/MODIFICATION

16B. UNITED

STATES OF AMERICA

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER

16A. NAME AND TITLE OF

CONTRACTING OFFICER

15B. CONTRACTOR/OFFEROR

STANDARD FORM 30

PREVIOUS EDITION NOT USABLE

Prescribed by GSA - FAR (48 CFR) 53.243 (Type or print) (Type or print) (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

(Number, street, county, State and ZIP Code) (If other than Item 6) (Specify type of modification and authority) (such as changes in paying office, appropriation date, etc.)

(If required)

(SEE ITEM 11)

(SEE ITEM 13)

(X)

CHECK

ONE

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF

SOLICITATIONS

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

(Signature of person authorized to sign) (Signature of Contracting Officer) None Department of Veterans Affairs

OPAL /

National Acquisition Center Building 37 1st Avenue, One Block North of Cermak Hines IL 60141 Department of Veterans Affairs OPAL / National Acquisition Center Building 37 1st Avenue, One Block North of Cermak Hines IL 60141 To all Offerors/Bidders

36E79724R0007 02-26-2024

X X X

3/7/2024, 2:30PM CT

X One Updating language in Continuation of SF-1449, Block 3 and extending the response due date.

This amendment is issued to update the language in the Continuation of SF-1449 Block 3, and to ext end the offer due date for solicitation 36E79724R0007 for BTK Inhibitors. The due date and time have been extended to March 7, 2024, 2:30PM Central Time.

See pages 2 - 3 for the updated Units per package and pages from the solicitation. Offerors shall enter their proposed prices, NDCs, Units per package, and alternate package size (if applicable).

All other terms and conditions of this solicitation remain unchanged.

Nicholas I. McGregor Contracting Officer

Continuation of SF-1449, Block 3:

The following information shall be entered by the Contracting Officer at the time of contract award according to the timeframes specified in this solicitation’s Section B, Scope of Contract, Section 1.4 Contract Effective Date, Implementation Period, and Ordering Period.

Contract Award/Effective Date: ___________________ Implementation Period: __________________________ Ordering Period (Base Year): _____________________

Offerors shall not enter information into the above fields.

Continuation of SF-1449, Blocks 19 through 24:

To be considered for award, offerors must submit a price for line item 1A, or 1B, or 1C for the base year and all four option years. One award will be made for line item 1A, or 1B, or 1C for the base year and all four option years. Offered prices shall not exceed two decimal places.

The price evaluation will be completed by multiplying the proposed BTK Inhibitors (Ibrutinib/Acalabrutinib/Zanubrutinib) price by the number of units per day required per patient to calculate a cost per day. This cost per day will then be multiplied by the estimated number of patients (a total of 2,444 for all participating agencies) for the proposed product and 365 (days per year) to calculate a total cost per year. The required number of units per patient per day are listed in the table for each item (1A, 1B, 1C) in the Schedule of Supplies and Attachment “B” of this solicitation. This method of price evaluation will ensure that the prices of proposed products can evaluated accurately and equitably. Unit prices offered shall not exceed two decimal places. The Government intends to evaluate offers and award a contract without discussions with offerors. However, the Government reserves the right to conduct discussions if determined by the Contracting Officer to be necessary.

The awarded product will be the only agent listed on the VA National Formulary for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) indications and will required be for new patient starts. The offeror must make all package sizes for the eligible strengths available. All proposed/awarded package sizes will be awarded at the same price per capsule/tablet.

Note: NDC is defined as National Drug Code. NDA is defined as New Drug Application.

Line Item 1A

Ibrutinib Capsules (140 MG)

NDC # __________________

NDA#_________________

Units per package: ___________

Alternate Package Size (if applicable):

NDC # __________________

Units per package: ___________

OR

Line Item 1B

Acalabrutinib Tablets (100 MG)

NDC # __________________

NDA#_________________

Units per package: ___________

Units per package: ___________

OR

Line Item 1C

Zanubrutinib Capsules (80 MG)

NDC # __________________

NDA#_________________

Units per package: ___________

Units per package: ___________